125.21
price down icon0.13%   -0.16
after-market  After Hours:  125.21 
loading
Merck & Co Inc stock is currently priced at $125.21, with a 24-hour trading volume of 4.78M. It has seen a -0.13% decreased in the last 24 hours and a +3.10% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $125.4 pivot point. If it approaches the $124.7 support level, significant changes may occur.

Merck & Co Inc Stock (MRK) Financials Data

Merck & Co Inc (MRK) Revenue 2024

MRK reported a revenue (TTM) of $60.11 billion for the quarter ending December 31, 2023, a +1.40% rise year-over-year.
loading

Merck & Co Inc (MRK) Net Income 2024

MRK net income (TTM) was $365.00 million for the quarter ending December 31, 2023, a -97.49% decrease year-over-year.
loading

Merck & Co Inc (MRK) Cash Flow 2024

MRK recorded a free cash flow (TTM) of $9.14 billion for the quarter ending December 31, 2023, a -37.83% decrease year-over-year.
loading

Merck & Co Inc (MRK) Earnings per Share 2024

MRK earnings per share (TTM) was $0.14 for the quarter ending December 31, 2023, a -97.55% decline year-over-year.
loading

Merck & Co Inc Stock (MRK) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Merck & Co., Inc.
10% Owner
Mar 11 '24
Buy
23.00
21,397,205
492,135,715
1,000
Davis Robert M
Chairman, CEO & President
Feb 14 '24
Option Exercise
73.73
85,021
6,268,598
433,348
Litchfield Caroline
EVP & CFO
Feb 14 '24
Option Exercise
58.08
38,291
2,223,941
89,199
Davis Robert M
Chairman, CEO & President
Feb 14 '24
Sale
125.40
85,021
10,661,574
348,327
Litchfield Caroline
EVP & CFO
Feb 14 '24
Sale
125.50
38,291
4,805,520
50,908
Davis Robert M
Chairman, CEO & President
Feb 13 '24
Option Exercise
74.18
150,000
11,127,160
498,327
Davis Robert M
Chairman, CEO & President
Feb 13 '24
Sale
125.85
150,000
18,877,424
348,327
Romanelli Joseph
President, Human Health Int?l
Feb 13 '24
Sale
124.89
1,000
124,888
19,569
Li Dean Y
Executive VP & President, MRL
Feb 09 '24
Option Exercise
62.07
14,702
912,553
60,944
Li Dean Y
Executive VP & President, MRL
Feb 09 '24
Sale
125.50
14,702
1,845,083
46,242
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. Merck & Co., Inc. has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, Premier Inc., Cue Biopharma, Inc., Foundation Medicine, Inc., Daiichi Sankyo Company, Limited, and Cold Genesys, Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
$164.66
price up icon 0.25%
drug_manufacturers_general JNJ
$145.74
price up icon 0.67%
drug_manufacturers_general NVS
$92.57
price down icon 0.55%
drug_manufacturers_general PFE
$25.39
price down icon 0.12%
$262.68
price down icon 0.53%
Cap:     |  Volume (24h):